Arena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Wednesday, September 22, 2010
Interesting Blog Article on Arena and analysts
The information at the end is specially interesting: The short interest is still 31% at this low price level.
That is very interesting, looks like institutions are betting against APPROVAL heavily.
ReplyDelete31% cannot be from retail investors